Alkem Laboratories Limited

rs,

.com 13 th May, 2022 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

24,839 million

mbai today. Key highlights of Q4FY22 financial performance • Total Revenue from Operations was~ 24,839 million, year-on-year growth of 13.3% o o India sales were~ 17,187 million, year-on-year growth of 16

13.3%

financial performance • Total Revenue from Operations was~ 24,839 million, year-on-year growth of 13.3% o o India sales were~ 17,187 million, year-on-year growth of 16.7% International sales were

17,187 million

venue from Operations was~ 24,839 million, year-on-year growth of 13.3% o o India sales were~ 17,187 million, year-on-year growth of 16.7% International sales were~ 7,411 million, year-on-year growth of 7.3

16.7%

on, year-on-year growth of 13.3% o o India sales were~ 17,187 million, year-on-year growth of 16.7% International sales were~ 7,411 million, year-on-year growth of 7.3% • Earnings before Interest

7,411 million

o o India sales were~ 17,187 million, year-on-year growth of 16.7% International sales were~ 7,411 million, year-on-year growth of 7.3% • Earnings before Interest, Tax, Depreciation and Amortization (EBIT

7.3%

ion, year-on-year growth of 16.7% International sales were~ 7,411 million, year-on-year growth of 7.3% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ~ 3,372 million, re

3,372 million

year growth of 7.3% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ~ 3,372 million, resulting in EBITDA margin of 13.6% vs. 13.3% in Q4FY21. EBITDA grew by 15.8% YoY • R&D expens

13.6%

t, Tax, Depreciation and Amortization (EBITDA) was ~ 3,372 million, resulting in EBITDA margin of 13.6% vs. 13.3% in Q4FY21. EBITDA grew by 15.8% YoY • R&D expenses for the quarter was~ 1,634 million,

15.8%

TDA) was ~ 3,372 million, resulting in EBITDA margin of 13.6% vs. 13.3% in Q4FY21. EBITDA grew by 15.8% YoY • R&D expenses for the quarter was~ 1,634 million, or 6.6% of total revenue from operations

1,634 million

margin of 13.6% vs. 13.3% in Q4FY21. EBITDA grew by 15.8% YoY • R&D expenses for the quarter was~ 1,634 million, or 6.6% of total revenue from operations compared to~ 1,408 million in Q4FY21 at 6.4% of total r

6.6%

. 13.3% in Q4FY21. EBITDA grew by 15.8% YoY • R&D expenses for the quarter was~ 1,634 million, or 6.6% of total revenue from operations compared to~ 1,408 million in Q4FY21 at 6.4% of total revenue fr

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 1011573 : 800 101 2045 : 800 964448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPass Reqistration/register?confirmationNumber=S724561 &linkS ecurityString=186ba84bb2 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE : ALKEM, BSE : 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APls) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands i